Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;20(2):176-85.
doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5.

Advances in anticancer immunotoxin therapy

Christine Alewine  1 , Raffit Hassan  1 , Ira Pastan  2
Affiliations
Review

Advances in anticancer immunotoxin therapy

Christine Alewine et al. Oncologist. 2015 Feb.

Abstract

Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing. Immunotoxins kill cells by inhibiting protein synthesis, a unique mechanism of action that is toxic to both dividing and nondividing cells. Recent advances in the design and administration of immunotoxins are overcoming historical challenges in the field, leading to renewed interest in these therapeutics.

Keywords: Antibody conjugate; Antidrug antibody; Recombinant immunotoxin; Vascular leak syndrome.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
Structure of select toxins and immunotoxins. Native Pseudomonas exotoxin A contains three domains: domain I (binding), domain II (unknown function), and domain III (catalytic domain). In the SS1P immunotoxin, domain I is replaced by a double-stranded Fv (VL and VH) that targets mesothelin. The engineered disulfide bond links VL and VH. The RG7787 immunotoxin uses a humanized Fab fragment and lacks PE domain II. Diphtheria toxin also contains three domains: catalytic, transmembrane, and binding. In denileukin diftitox, the B domain is replaced by human IL-2 to permit binding to cells bearing the IL-2 receptor. Gelonin is a plant toxin with n-glycosidase activity that inhibits ribosomal activity to halt protein synthesis. It consists of a single domain. In the hSGZ immunotoxin, recombinant gelonin is fused to a single-chain Fv (VL and VH) that binds fibroblast growth factor receptor 14-kDa protein (Fn14), and a bZIP domain that increases activity of the immunotoxin by allowing dimerization. Abbreviations: A, catalytic domain; B, binding domain; Gel, gelonin; IL-2, interleukin-2; rGel, recombinant gelonin; T, transmembrane domain.
Figure 2.
Figure 2.
Delivery of ADCs and immunotoxins. ADCs and immunotoxins bind to partners (HER-2, MSLN, or IL-R) on the cell surface and are internalized into an endocytic compartment. The ADC ado-trastuzumab maytansine traffics to lysosomes, where the maytansine chemotherapeutic is released from the antibody structure, allowing drug penetration into the cytosol, disruption of microtubule dynamics, and cell death (left). In endosomes, the modified PE toxin is cleaved from SS1P by the furin protease (middle). PE then undergoes retrograde transport through the Golgi to the endoplasmic reticulum. The method for egress from the endoplasmic reticulum to the cytosol is unknown. The toxin catalyzes irreversible ADP ribosylation of eEF2, leading to global inhibition of protein synthesis and cell death. The T domain (Fig. 1) of DT forms a pore in the membrane of the endosome, allowing transit of DT into the cytoplasm (right). Like PE, DT also catalyzes inhibitory modification of eEF2. Abbreviations: ADC, antibody-drug conjugate; ADP-ribose, adensodine diphosphate ribose; DT, diphtheria toxin; eEF2, eukaryotic elongation factor 2; IL-2, interleukin-2; IL-R, interleukin-2 receptor; MSLN, mesothelin; PE, Pseudomonas exotoxin A.
Figure 3.
Figure 3.
Durable response with SS1P plus lymphocyte-depleting regimen. Coronal computed tomography images of a responding patient 12 days after initiation of therapy on an SS1P, pentostatin, and cyclophosphamide clinical trial with durable response continuing at 24 months, more than 16 months after the last treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antignani A, Fitzgerald D. Immunotoxins: The role of the toxin. Toxins (Basel) 2013;5:1486–1502. - PMC - PubMed
    1. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822–1828. - PMC - PubMed
    1. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013;5:208ra147. - PMC - PubMed
    1. Collier RJ. Effect of diphtheria toxin on protein synthesis: Inactivation of one of the transfer factors. J Mol Biol. 1967;25:83–98. - PubMed
    1. Weldon JE, Pastan I. A guide to taming a toxin—recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278:4683–4700. - PMC - PubMed

Publication types

MeSH terms